This Medudy course is a video tutorial for physicians on the topic “The Urothelial Carcinoma Cohort of the Destiny-PanTumor02 Trial: Efficacy and Safety of Trastuzumab Deruxtecan in Patients with Metastatic HER2-Expressing (IHC 3+) Solid Tumors.”
In this video, Dr. Niklas Klümper, a senior physician in urology at the University Hospital of Bonn specializing in medical tumor therapy, summarizes the key findings of the DESTINY-PanTumor02 study and discusses their implications for everyday clinical practice in urologic oncology. In mid-2026, the approval of trastuzumab deruxtecan—T-DXd for short—was expanded to include inoperable or metastatic HER2-positive solid tumors with IHC-3+ status, based in part on the results of this study. The study evaluated the efficacy and safety of T-DXd in previously treated patients with HER2-expressing solid tumors. A clinically significant benefit was observed particularly in the subgroup with IHC-3+ status, to which the approval was accordingly limited. This also opens the door to a HER2-targeted treatment approach for previously treated metastatic urothelial carcinoma.
Note: All “speakers” appearing in the Medudy videos are AI-based avatars used to enhance the educational value of the videos. The individuals on whom the avatars are based have explicitly consented to their use. The video content was created and reviewed by the editorial team with the aid of AI, based on high-quality scientific sources, and has been approved by the speakers.
This course was made possible with the generous support of AstraZeneca.
By the end of this course, you will know:
- the mechanism of action of trastuzumab deruxtecan
- the results of the DESTINY-PanTumor02 study
- TDXd as a treatment option for inoperable or metastatic solid tumors with HER2 protein overexpression (IHC 3+ status)
- The Role of HER2 Diagnostics in Treatment Planning
